VERA Vera Therapeutics, Inc.

NASDAQ
$30.98

Vera Therapeutics, Inc. (VERA) is confirmed to report earnings on November 5, 2026, after the market close. The consensus earnings estimate is a loss of $1.72 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -3.1% since its last earnings release on August 10, 2026.

Vera Therapeutics Beat Consensus Estimates
Monday, August 10, 2026 · 4:05 PM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 5
Thursday · 4:05 PM ET
Earnings Whisper
-
vs ($1.72)
Rev est $2.62M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $32.17

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Vera Therapeutics, Inc.

Vera Therapeutics is a late clinical-stage biotechnology company focused on developing treatments for serious immunological diseases.

Sector

Healthcare

Industry

Biotechnology

Held By 1 ETFs, by dollar flow

Charts powered in part by Lightweight Charts™ by TradingView.